Research on capecitabine metronomic chemotherapy combined with oxaliplatin traditional chemotherapy in patients with advanced colon cancer

ObjectiveTo investigate the effects of capecitabine metronomic chemotherapy combined with oxaliplatin traditional chemotherapy on patients with advanced colon cancer. MethodsA total of 60 advanced colon cancer patients who were admitted in our hospital from August 2014 to August 2016 were collected and randomly divided into a research group and a control group (n=30). The research group was given capecitabine metronomic chemotherapy combined with oxaliplatin traditional chemotherapy, while the control group was provided with traditional doses of capecitabine combined with oxaliplatin traditional chemotherapy. Then, both groups were compared for the response rate (RR), disease control rate (DCR), KPS score, progression free survival (PFS) and adverse reactions during treatment. ResultsThe RR was 40% for the research group which was significantly different from 16.67% for the control (P<0.05). The DCR was 53.33% for the research group which was significantly different from 26.67% for the control (P<0.05). Before treatment, no statistical difference was found as to KPS between the two groups (P>0.05). However, after treatment, the research group was remarkable higher KPS scores than the control group (P<0.05). The PFS was (10.8±3.4) months for the research group which was significantly different from (8.3±2.5) months for the control (P<0.05). Compared with the control group, statistical differences were found as to gastrointestinal reaction, leukocyte count reduction, hand-foot syndrome, weakened immunity, neurotoxicity and other adverse reactions (P<0.05). ConclusionsCapecitabine metronomic chemotherapy combined with oxaliplatin traditional chemotherapy is effective and safe to treat advanced colon cancer.